Clinical Application of Iodine-125 Seed Brachytherapy Combined with Anti-PD-1 Antibodies in the Treatment of Lung Cancer.

Clinical Application of Iodine-125 Seed Brachytherapy Combined with Anti-PD-1 Antibodies in the Treatment of Lung Cancer.
Clin Ther. 2020 Jul 06;:
Authors: Sui A, Song H, Yu H, Zhang H, Hu Q, Lei Y, Zhang L, Wang J
Abstract
PURPOSE: The purpose of this case report was to investigate the clinical efficacy and tolerability of anti-programmed cell death protein (PD)-1 antibody combined with iodine (I)-125 seed brachytherapy in lung cancer treatment.
METHODS: Three patients with advanced PD-L1-positive non-small-cell lung cancer were treated first with I-125 seed brachytherapy and then with anti-PD-1 antibody. Clinical efficacy was evaluated with Response Evaluation Criteria in Solid Tumors.
FINDINGS: All 3 patients had complete response or partial response. None of the 3 patients had reported obvious adverse events.
IMPLICATIONS: Encouraging preliminary results provide important support for further clinical treatment of lung cancer using anti-PD-1 antibody combined with I-125 seed brachytherapy.
PMID: 32646546 [PubMed - as supplied by publisher]

Source: Clinical Therapeutics - July 5, 2020 Category: Drugs & Pharmacology Authors: Sui A, Song H, Yu H, Zhang H, Hu Q, Lei Y, Zhang L, Wang J Tags: Clin Ther Source Type: research